Company news
ImmuCell Corporation news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2023
August 9, 2023
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2023
August 6, 2023
ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 2023
July 10, 2023
ImmuCell Announces Change in Timing of Anticipated FDA Submission
June 27, 2023
ImmuCell Appoints Bryan K. Gathagan to Board of Directors
June 20, 2023
ImmuCell Announces Approval of Principal Terms of a $3 Million Debt Facility
June 14, 2023
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2023
May 10, 2023
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2023
May 3, 2023
ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 2023
April 4, 2023
ImmuCell Announces Unaudited Financial Results for the Year Ended December 31, 2022
February 20, 2023
ImmuCell to Announce Unaudited Financial Results for the Year Ended December 31, 2022
February 14, 2023
ImmuCell Announces Preliminary, Unaudited Sales Results for the Year Ended December 31, 2022
January 8, 2023
ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2022
November 20, 2022
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2022
November 9, 2022
ImmuCell Announces Preliminary, Unaudited Sales Results for Third Quarter of 2022
October 4, 2022
ImmuCell to Participate in the Lytham Partners Fall 2022 Investor Conference
September 13, 2022
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2022
August 10, 2022
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2022
August 3, 2022
ImmuCell Receives Technical Section Incomplete Letter from FDA Pertaining to Re-Tain®
July 26, 2022
ImmuCell Announces Preliminary, Unaudited Sales Results for Second Quarter of 2022
July 6, 2022
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2022
May 11, 2022
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2022
May 9, 2022
Dr. Mark Wustenberg joins ImmuCell as Commercial Leader of Stakeholder Engagement
May 4, 2022
ImmuCell Announces Record Preliminary, Unaudited Sales Results for First Quarter of 2022
April 10, 2022
ImmuCell Announces Unaudited Financial Results for the Quarter and Year Ended December 31, 2021
February 21, 2022
ImmuCell to Announce Unaudited Financial Results for the Quarter and Year Ended December 31, 2021
February 15, 2022
ImmuCell Announces Record Preliminary, Unaudited Sales Results for the Year Ended December 31, 2021
January 4, 2022
ImmuCell Announces Unaudited Financial Results for the Third Quarter Ended September 30, 2021
November 14, 2021
ImmuCell to Announce Unaudited Financial Results for the Third Quarter Ended September 30, 2021
November 8, 2021
ImmuCell Announces Record Preliminary, Unaudited Sales Results for Third Quarter of 2021
October 5, 2021
Raffael Lichdi, DVM Joins ImmuCell’s Sales & Marketing Team
September 13, 2021
ImmuCell Required to Prepare Second Submission of Final Major Technical Section for Re-Tain®
August 23, 2021
ImmuCell Announces Unaudited Financial Results for the Second Quarter Ended June 30, 2021
August 11, 2021
ImmuCell to Announce Unaudited Financial Results for the Second Quarter Ended June 30, 2021
August 4, 2021
ImmuCell Announces Strong Preliminary, Unaudited Sales Results for Second Quarter of 2021
July 6, 2021
ImmuCell Announces Unaudited Financial Results for the First Quarter Ended March 31, 2021
May 12, 2021
ImmuCell to Announce Unaudited Financial Results for the First Quarter Ended March 31, 2021
May 5, 2021
ImmuCell Closes $4,250,000 Equity Financing
April 13, 2021
ImmuCell Announces Preliminary, Unaudited Sales Results for First Quarter of 2021
April 6, 2021
ImmuCell Makes Important Regulatory Submission and Announces Unaudited Financial Results for the Year Ended December 31, 2020
February 21, 2021
ImmuCell to Announce Unaudited Financial Results for the Year Ended December 31, 2020
February 15, 2021
ImmuCell Announces Preliminary, Unaudited Sales Results for the Year Ended December 31, 2020
January 6, 2021
ImmuCell Announces Restructuring of its Bank Debt
December 14, 2020
ImmuCell Announces Unaudited Financial Results for the Third Quarter Ended September 30, 2020
November 11, 2020
ImmuCell to Announce Unaudited Financial Results for Third Quarter of 2020
November 4, 2020
ImmuCell Announces Preliminary, Unaudited Sales Results for the Quarter Ended September 30, 2020
October 5, 2020
ImmuCell Announces Unaudited Financial Results for the Second Quarter Ended June 30, 2020
August 11, 2020
ImmuCell to Announce Unaudited Financial Results for Second Quarter of 2020
August 5, 2020
ImmuCell Announces Preliminary, Unaudited Sales Results for the Second Quarter Ended June 30, 2020
July 6, 2020
ImmuCell Receives $500,000 Loan from the Maine Technology
June 15, 2020
Calls
The 5 newest of 22 calls. Every call is listed under its year.
- ImmuCell (NASDAQ:ICCC) Q2 2026 Earnings Call
Aug 14, 2026
Transcript - ImmuCell (NASDAQ:ICCC) Q1 2026 Earnings Call
May 15, 2026
Transcript - ImmuCell (NASDAQ:ICCC) Q4 2025 Earnings Call
Jan 9, 2026
Transcript - ImmuCell (NASDAQ:ICCC) Q3 2025 Earnings Call
Nov 14, 2025
Transcript - ImmuCell (NASDAQ:ICCC) Q2 2025 Earnings Call
Aug 15, 2025
Transcript
Decks
The 5 newest of 11 decks. Every deck is listed under its year.
- Q2 2026 Earnings Presentation
Earnings · 11 slides · Aug 14, 2026
- Investor Presentation (August 2026)
Investor deck · 39 slides · Aug 13, 2026
- Investor Presentation (May 2026)
Investor deck · 34 slides · May 15, 2026
- Q1 2026 Earnings Presentation
Earnings · 8 slides · May 15, 2026
- Investor Presentation (April 2026)
Investor deck · 31 slides · Apr 14, 2026